Search results
Pfizer's Paxlovid fails as 15-day treatment for long COVID, study finds
FOX Business· 3 hours agoA 15-day course of Pfizer's COVID-19 antiviral treatment Paxlovid did not relieve symptoms of long...
Thinking Of Buying Pfizer For Its 5.8% Dividend Yield? Consider This Alternative Option Instead
Benzinga via Yahoo Finance· 1 day agoPfizer Inc. (NYSE:PFE) has long been a favorite among income investors, thanks to its generous...
3 Stocks With Mouthwatering Dividends You Can Buy Right Now
Motley Fool via Yahoo Finance· 15 hours agoHere's why they picked Gilead Sciences (NASDAQ: GILD), Organon (NYSE: OGN), and Pfizer (NYSE: PFE)....
Pfizer Lingers Near 11-Year Low Despite Promising Cancer Drug Updates — Is It A Sell?
Investor's Business Daily· 2 days agoDespite a bevy of promising updates for its cancer treatments, Pfizer stock remains trapped below a...
Want $1,000 in Dividend Income? Here's How Much You'd Have to Invest in Pfizer Stock. | The Motley...
The Motley Fool· 12 hours agoGenerating dividend income can be an excellent way to put your cash to work. Pfizer pays a quarterly...
Is Pfizer Inc. (NYSE:PFE) the Best Gene Therapy Stock to Buy Now?
Insider Monkey via Yahoo Finance· 5 days agoWe recently compiled a list of the 9 Best Gene Therapy Stocks to Buy Now and in this article, we...
US FDA expands GSK's RSV vaccine approval to adults aged 50 to 59
Reuters via Yahoo News· 1 day agoThe shot, branded Arexvy, and vaccines from rivals Pfizer and Moderna are already approved for...
New COVID variant KP.3 climbs to 25%, now largest in CDC estimates
CBS News· 1 day agoThe new KP.3 variant has climbed to 1 in 4 new COVID-19 cases nationwide, the Centers for Disease...
Promising Trial Results Show New Standards In Cancer Treatment And Diagnostics Are On The Horizon
Benzinga via Yahoo Finance· 4 days agoOn Friday, Pfizer Inc (NYSE: PFE) revealed its drug for an advanced form of lung cancer showed...
Why Things Could Get Worse for Pfizer Stock Before They Get Better
Motley Fool via Yahoo Finance· 4 days agoA few years ago, in the race to launch a COVID-19 vaccine, Pfizer (NYSE: PFE) stock was a hot buy...